History

Established in 2015, Stallergenes Greer combines a hundred years of allergy expertise of Greer in the United States with Stallergenes’ history of innovation in immunotherapy from a base in France.

As a company 100% dedicated to the research and development of innovative treatment of allergies, Stallergenes Greer adopts a comprehensive approach to addressing and managing allergic diseases, offering allergy specialists a wide range of products, from diagnosis to sublingual and subcutaneous allergy immunotherapy. Its core business is researching, developing, manufacturing and marketing innovative allergen immunotherapy medicines.

With a strong focus on innovation, the Group is at the origin of a new generation of allergy immunotherapy treatments. Upon its creation, Stallergenes Greer brought an essential contribution to allergy therapies at a time when symptomatic treatments were the gold standard. These efforts have considerably strengthened the level of evidence supporting allergy immunotherapy.

Allergy immunotherapy innovation has evolved significantly over the years. Stallergenes Greer has never stopped innovating in order to meet the needs of patients and to consolidate its knowledge and expertise in the field of innovative treatments with a view to developing products that seek to optimise treatment and management of patients with allergies. As the years have gone by, allergy immunotherapy innovation has evolved significantly.

References:

  • Novak N, et al. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 2011;66:733-9.
  • Eifan AO, et al. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol 2011;11:586-593.

TIMELINE

2016

Stallergenes Greer

Launch of ACTAIR® in Australia and approval in South Korea

Positive results achieved for STG120 Japanese Cedar Phase II study

2015

Stallergenes Greer

Shareholders approve the combination of Stallergenes and Greer Laboratories leading to the creation of the world leader in allergy immunotherapy.

Launch of ACTAIR® in Japan with Shionogi & Co., Ltd, first immunotherapy tablet for the treatment of house dust mite (HDM) induced allergic rhinitis in adolescents and adults.

Temporary suspension of production and distribution at our Antony plant, France

2014

Stallergenes & GREER®

ORALAIR®, a 5-grass sublingual immunotherapy tablet, receives FDA approval in the U.S. US marketing authorization for the 5 grass pollen allergen immunotherapy tablet, Oralair® granted by the Food and Drug Administration (FDA).

2013

Stallergenes & GREER®

Greer Laboratories Inc., one of the leading US pharmaceutical companies in the field of allergen immunotherapy, and Stallergenes sign exclusive agreement for the commercialization of the 5 grass pollen allergen immunotherapy tablet, Oralair®, in the US.

2013

GREER®

USDA approves veterinary allergenic extracts for sublingual immunotherapy administration.

2012

Stallergenes

Launch in France and Canada of the 5-grass pollen allergen immunotherapy tablet, Oralair®. Positive clinical results for the house dust mites sublingual immunotherapy tablets.

2012

GREER®

GREER® enters into Global supply agreement with IDEXX, a leader in pet healthcare innovation.

2010

Stallergenes

Stallergenes and Shionogi & Co. Ltd, a leading Japanese pharmaceutical company, signed an exclusive partnership agreement for the development of 2 sublingual immunotherapy tablets in Japan: house dust mite tablets and Japanese cedar pollen tablets.

2009

Stallergenes

Registration of the 5-grass sublingual immunotherapy tablet, Oralair®, as a pharmaceutical specialty for adults and children in 23 European countries.

2008

Stallergenes

Opening of an ultra-modern production unit in Antony (Paris area) dedicated to manufacturing the active ingredient in sublingual immunotherapy tablets, leading to a tenfold increase in production capacity.

2007

Stallergenes

Efficacy of the 5-grass sublingual immunotherapy tablet demonstrated among children.

2005

Stallergenes

Positive results for a new form of Allergen immunotherapy : 5-grass sublingual allergen tablet which efficacy is demonstrated among adults.

2004

GREER®

GREER® celebrated 100 years in business, receives approval for use of GREER® cultured mites in the manufacture of extracts and, the same year, launches Aller-g-complete, Vet Serology Testing and Immunotherapy Service.

2003

Stallergenes

Specific and patented house dust mite culture medium established : Stalmite APF® (Animal Protein Free). The company is a pioneer and the leader in production of pharmaceutical level house dust mites.

2003

GREER®

Launch of the Skintestor OMNI™, multiple-site skin test device.

2002

Stallergenes

European launch of high-dose sublingual immunotherapy Staloral® allowing for a new expansion phase.

2002

GREER®

GREER® Pharmacy, a licensed specialty pharmacy for immunotherapy compounding needs, started to fill prescriptions for physicians and veterinarians.

1999

Stallergenes

With the purchase of DHS, Bayer Pharma’s Allergy division, the Stallergenes Group became the world’s no 2 company in its field.

1998

Stallergenes

Initial Public Offering on the second market of the Paris stock exchange.

1997

Stallergenes

Commissioning of a new fully-automated NPPs production line in Antony.

1996

Stallergenes

Relocation of the head office and production site to Antony (Paris area) enabling Stallergenes to acquire the equipment and infrastructure necessary for its expansion and optimizing the production of NPPs.

1993

Stallergenes

Pasteur Mérieux ceded control of Stallergenes to the Wendel Group (known at the time as Marine-Wendel).

1992

Stallergenes

Launch of Staloral® and first pharmaceutical paper given on the sublingual route at the EAACI congress (European Academy of Allergy and Clinical Immunology) recognizing Stallergenes’ major contribution to the development of sublingual immunotherapy.

1991

Stallergenes

Start of in-house production of house dust mites. Stallergenes becomes the leading pharmaceutical producer worldwide.

1989

Stallergenes

Merger with the Institut Pasteur’s allergen division, allowing Stallergenes to become a leader in allergen immunotherapy. Stallergenes and Institut Pasteur merged their manufacturing activities and began a joint allergen research project.

1989

GREER®

Launch of GREER®Pick®, a single-site skin testing device.

1988

Stallergenes

First NPPs (Named Patient Products) automated production line increasing the rate of production. A line continually upgraded and still advanced worldwide.

1986

Stallergenes

Stallergenes developed and supplied the very first oral anti-allergy immunotherapy treatment.

1986

GREER®

GREER® received FDA approval of labeling for extracts for diagnostic use only.

1985

Stallergenes

First standardization of biological allergens in IR (index of reactivity) dose units. The aim of standardization is to guarantee the ability to reproduce biological products.

1984

GREER®

New manufacturing facility opens in Lenoir, North Carolina.

1983

GREER®

GREER® received licenses from U.S. Department of Agriculture (USDA) for allergenic extracts for Veterinary use.

1974

Stallergenes

Head office established in Fresnes (Paris area) with the goal of developing activities independently.

1971

GREER®

GREER® introduced Dia-Kit, a diagnostic aid for hypersensitivity pneumonitis.

1962

Stallergenes

Stallergenes created in Lyon (France) by Institut Mérieux, the world leader in vaccines.

1962

GREER®

GREER® started filling name-patient sets.

1958

GREER®

GREER® obtained Product License from the US Food and Drug Administration (FDA) for the manufacture for sale of Allergenic Extracts. Specific approvals for standardized extracts were received in subsequent years.

1904

GREER®

GREER® was established by R.T. Greer as a collecter of source materials (i.e. : roots, herbs, pollens).